pDCs, distinguished by their ability to produce large amounts of type I IFN upon viral infection (30–33) are identified, in humans, by the expression of surface markers CD303 (BDCA-2), CD304 (BDCA-4/Neuropilin) and CD123 (5, 13). This evidence concerns the gene CLEC4C and viral infectious disease.